Sergio Traversa

This profile gathers the share dealings of Sergio Traversa across 2 companies, led by Relmada Therapeutics, Inc. and Actinium Pharmaceuticals, Inc. Over a trading history stretching from 14 April 2016 to 10 September 2026, the count stands at 55 filings.

The open-market side counts 19 purchases for €2.5M alongside 24 sales for €2.0M. On balance, insiders were net buyers of €505k. Open-market purchases are the filings investors watch most closely, because the insider pays for the shares out of pocket. Other entries cover 1 share grant and 11 option exercises. 2026 to date brings 2 purchases and no sales.

The median purchase comes to €97k. Of 19 purchases, 15 formed part of a group of insiders buying within 30 days of each other. Purchases made close together by different insiders form what is called a cluster. Ninety days after publication, 7 purchases show a median change of +19.7%, with the price up in 57% of them. This is a record of the past, not a forecast.

On 11 September 2026 came the latest disclosure, an open-market purchase for €359k in Relmada Therapeutics, Inc. Filings reach the SEC (Form 4) feed a median of 2 days after the trade. Section 16 rules allow two business days to file each Form 4. Keep in mind that insiders sell for many reasons unrelated to the outlook, from tax bills to estate planning. Every figure here comes from the filings published by SEC (Form 4) and describes the past, not future prices; it is not investment advice.